Procedures and Treatments
bladder tumor, TURBT, Tumor
BLADDER TUMOR, TUMOR
During the screening process, all patients underwent a transurethral resection of bladder tumor (TURBT) and underwent imaging (CT or MRI) to assess local and metastatic lesions. Patients were required to have pathologic evidence of muscle invasion in the TURBT specimen prior to enrollment. Tumor tissue and peripheral blood were collected for biomarker analysis.In the single‐arm stage, patients received neoadjuvant treatment 2 weeks after TURBT. To minimize the time to surgery and potential AEs, three cycles of camrelizumab plus GC were administered. Each cycle consisted of camrelizumab 200 mg intravenously (IV) once on day 1, gemcitabine 1000 mg/m